Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-49.87M | $-1.96 |
| 2024 | $0.00 | $-62.88M | $-3.51 |
| 2023 | $0.00 | $-15.7K | $-3.42 |
| 2022 | $0.00 | $-27.3K | $-6.02 |
| 2021 | $0.00 | $-26.2K | $-5.89 |
Social Signal Score
Earnings
Fri, Nov 13(in 3 months)
Consensus estimate $-0.10 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.10 vs $-0.17beat
- Fri, May 15$-0.19 vs $-0.49beat
- Thu, Mar 26$-1.09 vs $-1.09beat
- Fri, Nov 14$-0.21 vs $-0.24beat
- Thu, Aug 14$-0.28 vs $-0.22miss
- Mon, Apr 7$-0.26 vs $-0.14miss
Estimates and results for RNTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
RNTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Neutral
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
View source ↗